贝伐珠单抗联合FOLFIRI方案治疗氟尿嘧啶耐药的晚期结直肠癌患者的疗效

doi:10.3969/j.issn.1671-7171.2025.02.026

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (1280 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To investigate the clinical efficacy of bevacizumab combined with the FOLFIRI regimen in treating fluorouracil (FU)-resistant advanced colorectal cancer (CRC) patients.【Methods】A total of 89 FU-resistant advanced colorectal cancer patients were randomly divided into two groups: the control group (44 patients, treated with the FOLFIRI regimen) and the observation group (45 patients, treated with bevacizumab combined with FOLFIRI regimen). The short-term and long-term efficacy, changes in tumor marker levels before and after treatment, and adverse reactions were compared between the two groups.【Results】The short-term overall response rate was significantly higher in the observation group than in the control group (P<0.05). After treatment, serum levels of carbohydrate antigen 19-9 (CA19-9), carbohydrate antigen 242 (CA242), carcinoembryonic antigen (CEA), and epidermal growth factor receptor (EGFR) were significantly lower than before treatment (P<0.05) in both groups, and the observation group had lower levels compared to the control group (P<0.05). At the end of the follow-up period, the median overall survival (OS) of the control group was 12.0 months, while the OS of the observation group was 17.0 months; the Kaplan-Meier curve comparison between the two groups showed a significant statistical difference (Log-rank χ²=5.624, P=0.018). There were no significant differences in the incidence of adverse reactions between the two groups (P>0.05).【Conclusion】Bevacizumab combined with FOLFIRI regimen treatment improves both short- and long-term efficacy in FU-resistant advanced colorectal cancer patients, reduces tumor marker levels, and it is safe and reliable.

Key words： Colorectal Neoplasms Bevacizumab Fluorouracil Treatment Outcome

Received: 06 October 2023

PACS:

R735.35

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	SUN Zhenmin
	LI Ting

Cite this article:

SUN Zhenmin,LI Ting. Efficacy of Bevacizumab Combined with FOLFIRI Regimen in the Treatment of Fluorouracil-Resistant Advanced Colorectal Cancer[J]. JOURNAL OF CLINICAL RESEARCH, 2025, 42(2): 265-267.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2025.02.026 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2025/V42/I2/265

[1] FRANCIPANE M G, BULANIN D, LAGASSE E. Establishment and characterization of 5-fluorouracil-resistant human colorectal cancer stem-like cells: tumor dynamics under selection pressure[J].Int J Mol Sci,2019, 20(8):1817.
[2] 李小峰, 孙新宇, 郝光军, 等. 腹腔内贝伐珠单抗辅助卵巢癌术后化疗对患者血清AFP、VEGF、TGF-β1、MIF的影响[J].现代生物医学进展, 2022, 22(2):379-382.
[3] 李金燕, 吕伯乐, 吕姗, 等. 贝伐珠单抗联合化疗对晚期肺癌患者血清肿瘤标志物及免疫功能的影响[J].癌症进展, 2021, 19(18):1896-1899.
[4] 姚宏伟, 刘荫华. NCCN结直肠癌临床实践指南2011年更新解读[J].中华胃肠外科杂志, 2011, 14(4):234-238.
[5] LITIÈRE S, ISAAC G, DE VRIES E G E, et al. RECIST 1.1 for response evaluation apply not only to chemotherapy-treated patients but also to targeted cancer agents: a pooled database analysis[J].J Clin Oncol,2019, 37(13):1102.
[6] HUGHES R. NCI-CTC vs TNS: which tool is better for grading the severity of chemotherapy-induced peripheral neuropathy?[J].Nat Clin Pract Neurol,2008, 4(2):68-69.
[7] DEKKER E, TANIS P J, VLEUGELS J L A,et al. Colorectal cancer[J].Lancet,2019, 394(10207):1467-1480.
[8] KONG F, MUIR J. 5-Fluorouracil: friend or foe?[J].Aust J Gen Pract,2021, 50(8):557-559.
[9] SCHMITT M, GRETEN F R. The inflammatory pathogenesis of colorectal cancer[J].Nat Rev Immunol,2021, 21(10):653-667.
[10] LI J, MA X, CHAKRAVARTI D, et al. Genetic and biological hallmarks of colorectal cancer[J].Genes Dev,2021, 35(11-12):787-820.
[11] 王奇龙, 陈南征, 吕铁升. 血清CEA、CA19-9、CA242对结直肠癌转移及预后的评估价值[J].解放军医药杂志, 2020, 32(6):29-33.
[12] ENRÍQUEZ-ACEVES I, GALICIA-CARMONA T, CORONEL-MARTÍNEZ JA, et al. Standard treatment with bevacizumab as targeted therapy in cervical cancer[J].Rev Invest Clin,2020, 72(4):213-218.
[13] ZHU M, COSTELLO B A, YIN J, et al. Phase Ⅱ trial of bevacizumab monotherapy in pancreatic neuroendocrine tumors[J].Pancreas,2021, 50(10):1435-1439.
[14] PRAGER G W, TAIEB J, FAKIH M, et al. Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer[J].N Engl J Med,2023, 388(18):1657-1667.
[15] SEHNALOVÁ I,ŘÍHOVÍ B, DEMLOVÁ R. Bevacizumab treatment in metastatic colorectal carcinoma:an economic perspective[J].Ceska Slov Farm,2019, 68(2):43-47.